First patient has been treated in the RAD-18-002 phase 2A clinical study

All dose levels of Radspherin® were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study. Radspherin® is currently being evaluated in two ongoing Phase 1 trials for the treatment of peritoneal carcinomatosis from ovarian cancer and colorectal cancer

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming virtual investor conferences:

Twenty-three colorectal cancer patients in total have been enrolled in the Radspherin® RAD-18-002 phase 1 clinical trial and treated with Radspherin®. No SAE’s related to the Radspherin® treatment have been observed.

Oncoinvent presents preclinical dosimetry data documenting a therapeutic relevant biodistribution of Radspherin® as well as preclinical data on the potential synergistic effects of Radspherin® with existing cancer therapies. The company also will present preclinical results of a novel 212Pb product candidate

The company makes three important new appointments to the clinical and regulatory teams in preparation for the upcoming Radspherin® phase 2 clinical trials

Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-001 study to fourth and final cohort dose level cohort

Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin®

Norwegian radiopharmaceutical company is contemplating a private placement to raise funds for the phase 2A development of it’s lead product candidate Radspherin®

7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study